ClinicalTrials.gg
RecruitingNCT07412769Updated Feb 17, 2026

ASMact: Study on Management of Bronchial Asthma

An observational study in Asthma Acute, Asthma Childhood and Asthma in Children, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 2 sites in Italy. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Meyer Children's Hospital IRCCS · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.

Planned enrollment
15th of 47
500 · median 152
Started
2025
with 6 others
Observational
47 of 177
6 open now
Primary completion
2026-05
later than 7 of 28 live
Registered
172nd of 177
by date

Among the 177 studies in Asthma with a site in Italy, this one is the 15th largest by planned enrollment of the 47 observational ones that give a count, is one of 7 that started in 2025, is one of 47 observational ones, reaches primary completion later than 7 of the 28 other live ones, and was the 172nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Asthma with a site in Italy, or all of them as a file.
02

Study summary

Standardization According to GINA 2025 Recommendations for the Treatment, Management, and Follow-up of Acute Asthma Attacks: Observational, Multicenter Cohort Study.

Read the detailed description

Patients aged 6 to 17 years presenting to the emergency department with an acute asthma exacerbation were included. Clinical outcomes were compared between a pre-intervention period (October 2024-May 2025) and a post-intervention period (October 2025-May 2026).

Between the two study periods, a structured educational intervention targeting medical and nursing staff was implemented. The intervention consisted of didactic lectures, clinical simulation sessions, case-based discussions, and the dissemination of updated diagnostic and therapeutic flowcharts based on the 2025 Global Initiative for Asthma (GINA) guidelines.

03

Conditions studied

  • Asthma Acute
  • Asthma Childhood
  • Asthma in Children
  • Asthma Crisis

Browse trials for

Keywords

  • asthma attack, exacerbation,
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of pediatric patients aged 6 to 17 years presenting to the emergency departments of two Italian tertiary-care hospitals (AOU IRCCS Meyer Children's Hospital in Florence and Arcispedale S. Anna in Ferrara) with an acute asthma exacerbation.

Eligible patients were identified through retrospective review of electronic medical records of all emergency department visits occurring during the predefined study periods. Patients were included if they received a discharge diagnosis consistent with acute asthma exacerbation or related conditions (e.g., bronchospasm, asthma attack, asthmatic bronchitis, wheezing).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 6 and 17 years
  • Presentation to the emergency department with a diagnosis of acute asthma exacerbation
  • Evaluation in the emergency department of one of the participating centers during the study periods

Exclusion criteria

Exclusion Criteria:

  • Age \< 6 years or > 17 years
  • Diagnosis other than acute asthma exacerbation
  • Incomplete or missing clinical data
  • Patients transferred from other hospitals already treated for the same episode
  • history of allergy to any drugs used in the protocol
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pre-intervention cohort

    Pediatric patients aged 6-17 years presenting to the emergency department with an acute asthma exacerbation during the pre-intervention period (October 2024-May 2025). Patients received standard care according to local clinical practice prior to the implementation of the structured educational intervention. Intervention: No intervention (standard of care)

  • Post-intervention cohort

    Pediatric patients aged 6-17 years presenting to the emergency department with an acute asthma exacerbation during the post-intervention period (October 2025-May 2026), after the implementation of a structured educational intervention for emergency department staff. Intervention: Educational intervention (health care provider-directed)

06

What researchers measure

Primary outcomes

  1. Change in the number of correctly reported diagnoses before and after intervention

    Assessment of adherence to guideline-based diagnostic and therapeutic management of pediatric patients presenting with acute asthma exacerbations in the emergency department.

    Time frame: Pre-intervention and through study completion, an average of 9 months

  2. Percentage of patients with correct timing, dosage, and method of drug administration before and after intervention

    Time frame: Pre-intervention and through study completion, an average of 9 months

  3. Percentage of patients with correct follow-up at discharge

    Time frame: Pre-intervention and through study completion, an average of 9 months

  4. Percentage of patients in whom additional drugs are used in refractory cases

    Time frame: Pre-intervention and through study completion, an average of 9 months

  5. Percentage of patients with correct therapy at discharge

    Time frame: Pre-intervention and through study completion, an average of 9 months

Secondary outcomes

  1. Incidence of acute asthma exacerbations

    Number of emergency department visits for acute asthma exacerbations among pediatric patients during the pre- and post-intervention periods.

    Time frame: Pre-intervention and through study completion, an average of 9 months

07

Study locations

2 of 2 sites recruiting
  • Arcispedale S. Anna
    Ferrara, FE 44124, Italy
    Recruiting
    • Luca Di Napoli, MD · Contact
  • Meyer Children's Hospital IRCCS, Firenze
    Florence, 50134, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2026, 6 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 6 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 17, 2026
StartActual
Nov 5, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07412769
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Grazia Fenu (Principal Investigator, Meyer Children's Hospital IRCCS) — Principal investigator
First posted
Feb 17, 2026
Start date
Nov 5, 2025
Primary completion
May 31, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Grazia Fenu
Contact
grazia.fenu@meyer.it
+390555662388 ext. +390555662388

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion